Ultimately, the objective is to obtain an antibody that works in your application with your target protein. While no-one can guarantee this, what should be done is to create the best possible conditions - within a reasonable budget - for the successful outcome of your antibody project. The topic is vast, and the following links cover some of the aspects that need to be taken into consideration.
For a custom antibody project, ELISA testing is a useful tool for showing that the immunisation has been successful. However, without a standard the results do not say more than: Yes, antibodies against the intended target are present in the sample. Since there is no standard for your custom antibody, any reported value must essentially be treated as a binary (i.e. positive/negative).
There are two common definitions of antiserum titre;
When the antigen is a synthetic peptide produced by us, we guarantee that the antiserum tests positive in our ELISA. Typically the EC50 is 1:20000 and the end point titre > 1:1000000 (as of March 2012, median for the last 1000 ELISA tests)
When effort has been put into the antigen design and production, and a robust immunisation protocol is employed, chances are good that working antibodies will be obtained in the end. When a custom antibody project is allowed to take its time, the results are likely to be better, and since the ultimate goal is to obtain quality antibodies these projects are typically not rushed. It is however possible to accommodate a pre-defined and fixed time-frame, meaning that immune serum can be delivered on-time. When a time definite service explicitly ordered, we guarantee that the antiserum is delivered on time. Typically our standard protocol is followed, in which case the first serum sample is prepared six weeks after primary injection, although earlier bleeds could be made, as mentioned in our article on rapid antibody development..
When turning to us for your antibody requirements, our expertise is made available for the benefit of your project. We are looking forward to provide service and support from peptide design to delivery of your antibodies.
Innovagen was founded in 1992 and has provided research materials to the scientific community ever since. We have been involved in thousands of custom antibody projects over the years, and our knowledge and our commitment to quality in all aspects of the antibody production process is a result from the extensive experience that we have accumulated.
Examples of references of customers using our custom polyclonal antibody services include;
R. Bahtz, J. Seidler, M. Arnold, U. Haselmann-Weiss, C. Antony, W. D. Lehmann and I. Hoffmann
GCP6 is a substrate of Plk4 and required for centriole duplication
Journal of Cell Science, February 2, 2012 doi: 10.1242/jcs.093930
T. Steinfeldt, S. Könen-Waisman, L. Tong, N. Pawlowski, T. Lamkemeyer, L. D. Sibley, J. P. Hunn & J. C. Howard. 2010.
Phosphorylation of Mouse Immunity-Related GTPase (IRG) Resistance Proteins Is an Evasion Strategy for Virulent Toxoplasma gondii.
PLoS Biol 8(12): e1000576. doi:10.1371/journal.pbio.1000576
A.-C. Lindås, E. A. Karlsson, M. T. Lindgren, T. J. G. Ettema, and R. Bernander. 2008. A unique cell division machinery in the Archaea. PNAS December 2, 2008 vol. 105 no. 48 18942-18946.
L. Camper, U. Hellman, E. Lundgren-Åkerlund
Isolation, Cloning, and Sequence Analysis of the Integrin Subunit α10, a β1-associated Collagen Binding Integrin Expressed on Chondrocytes.
The Journal of Biological Chemistry, August 7, 1998, vol 273, 20383-20389.
| Postal address |
| Innovagen AB SE-22370 Lund SWEDEN |
| Telephone | |
| Switchboard Fax | +46 46 286 20 60 +46 46 18 81 71 |
| General information |
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies. More information available here.